Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;25(12):845-855.
doi: 10.1089/dia.2023.0323. Epub 2023 Nov 7.

Listening to Women: Experiences of Using Closed-Loop in Type 1 Diabetes Pregnancy

Affiliations

Listening to Women: Experiences of Using Closed-Loop in Type 1 Diabetes Pregnancy

Julia Lawton et al. Diabetes Technol Ther. 2023 Dec.

Abstract

Introduction: Recent high-profile calls have emphasized that women's experiences should be considered in maternity care provisioning. We explored women's experiences of using closed-loop during type 1 diabetes (T1D) pregnancy to inform decision-making about antenatal rollout and guidance and support given to future users. Methods: We interviewed 23 closed-loop participants in the Automated insulin Delivery Among Pregnant women with T1D (AiDAPT) trial after randomization to closed-loop and ∼20 weeks later. Data were analyzed thematically. Results: Women described how closed-loop lessened the physical and mental demands of diabetes management, enabling them to feel more normal and sleep better. By virtue of spending increased time-in-range, women also worried less about risks to their baby and being judged negatively by health care professionals. Most noted that intensive input and support during early pregnancy had been crucial to adjusting to, and developing confidence in, the technology. Women emphasized that attaining pregnancy glucose targets still required ongoing effort from themselves and the health care team. Women described needing education to help them determine when, and how, to intervene and when to allow the closed-loop to operate without interference. All women reported more enjoyable pregnancy experiences as a result of using closed-loop; some also noted being able to remain longer in paid employment. Conclusions: Study findings endorse closed-loop use in T1D pregnancy by highlighting how the technology can facilitate positive pregnancy experiences. To realize fully the benefits of closed-loop, pregnant women would benefit from initial intensive oversight and support together with closed-loop specific education and training. Clinical Trial Registration number: NCT04938557.

Keywords: Closed-loop; Pregnancy; Quality-of-life; Type I diabetes; Women's experiences.

PubMed Disclaimer

Conflict of interest statement

S.H. serves as a member of the Medtronic advisory board, is a director of Ask Diabetes Ltd. providing training and research support in health care settings, and reports having received training honoraria from Medtronic, Dexcom, and Ypsomed, and consulting fees for CamDiab. T.T.M.L. reports having received a personal research grant from the Diabetes Research and Wellness Foundation Sutherland-Earl Clinical Fellowship. A.R.D. reports receiving royalties from Elsevier for author contributions to the textbook “Macleod's Clinical Examination”; and honoraria from Abbott Ltd. R.H. reports having received speaker honoraria from Dexcom, Eli Lilly, and Novo Nordisk, serving on advisory panel for Eli Lilly and Novo Nordisk; receiving consulting fees from Abbott Diabetes Care; receiving licensing fees from BBraun and Medtronic; patents related to closed-loop insulin delivery; and being a shareholder and director at CamDiab. H.R.M. sits on the Medtronic UK and European Scientific Advisory Board and reports receiving speaker honoraria from Dexcom, Abbott, Medtronic, Sanofi, and Novo Nordisk; chairing the National Pregnancy in Diabetes (NPID) audit; and is a member of the editorial board for Diabetes Care and Diabetologia. J.L., B.K., M.C., D.R., R.M.R., K.B.-K., and C.C. have no conflicts of interest to declare.

References

    1. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care 2019;42:1593–1603. - PMC - PubMed
    1. Singh H, Ingersoll K, Gonder-Frederick L, et al. “Diabetes just tends to take over everything”: Experiences of support and barriers to diabetes management for pregnancy in women with type 1 diabetes. Diabetes Spectr 2019;32:118–124. - PMC - PubMed
    1. King R, Wellard S. Juggling type 1 diabetes and pregnancy in rural Australia. Midwifery 2009;25:126–133. - PubMed
    1. Murphy HR, Howgate C, O'Keefe J, et al. Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: A 5-year national population-based cohort study. Lancet Diabetes Endocrinol 2021;9:153–164. - PubMed
    1. Tundidor D, Meek CL, Yamamoto J, et al. Continuous glucose monitoring time-in-range and HbA1c targets in pregnant women with type 1 diabetes. Diabetes Technol Ther 2021;23:710–714. - PMC - PubMed

Publication types

Associated data